16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines.
The report describes developments in meningococcal disease vaccines presented at the 16th International Pathogenic Neisseria Conference, Rotterdam, 7-12 September 2008. Great progress has been made by the Meningitis Vaccine Project to provide an affordable and effective serogroup A conjugate vaccine for use in the meningitis belt of Sub-Saharan Africa. The vaccine has been shown to be safe and to produce excellent immune response in phase 2 clinical trials in India and Africa in the target populations and will be rolled out to the worst affected countries from 2009. This vaccine has the potential to make a huge impact on public health in this region. This conference heard that the use of an epidemic strain-specific outer membrane vesicle (OMV) vaccine in New Zealand has been discontinued. Views for and against this decision were presented. Several MenB vaccines have progressed to clinical evaluation. The most advanced are the Novartis five recombinant protein variants and the Wyeth vaccine based on two factor H binding protein variants. Promising results from both vaccines with genetically-detoxified lipooligosaccharide and overexpressed heterologous antigens, OMV's from Neisseria lactamica and recombinant Opa proteins.
Gorringe
Andrew R
AR
Health Protection Agency, Center for Emergency Preparedness and Responses, Porton Down, Salisbury, UK. andrew.gorringe@hpa.org.uk
van Alphen
Loek
L
D035843:Biomedical Research / Q000639:trends; D002986:Clinical Trials as Topic; D006801:Humans; D008585:Meningitis, Meningococcal / Q000382:microbiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology*
D022401:Meningococcal Vaccines